The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...

Of the 37.1 million patients with type 2 diabetes, 810,390 were new semaglutide users, 326,282 were treated with dulaglutide, 25,936 with exenatide (Byetta, Bydureon), 715,802 with empagliflozin ...

GPs are free to prescribe semaglutide to all eligible patients in line with NICE guidelines after long-term shortages have ...

Adults with type 2 diabetes using semaglutide, dulaglutide (Trulicity, Eli Lilly), exenatide, empagliflozin (Jardiance, Boehringer Ingelheim), sitagliptin (Januvia, Merck) or glipizide from ...

showing that once-weekly semaglutide significantly reduced HbA1c and body weight in persons with type 2 diabetes when compared to dulaglutide. Additionally, the obesity segment is predicted to ...

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).